Physician profile
Soo Ryum Yang
NPI 1669892105
$59,574.65
in general payments reported to CMS, 2019-2025
9 companies · $26K in 2025
The $26K reported for 2025 was more than what 97% of Anatomic Pathology & Clinical Pathology providers received nationally (typical 2025 total: $50.59).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $18K · 2024: $15K · 2025: $26K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $33K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17K · Travel and Lodging: $8,281 · Education: $850 · Food and Beverage: $616.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $33,254.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,573.98 |
| Travel and Lodging | $8,280.90 |
| Education | $850.00 |
| Food and Beverage | $615.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Uk Limited | $16,081.00 | 2023 | |
| Abbvie INC. | $15,055.55 | 2024-2025 | |
| Roche Diagnostics Corporation | $11,815.79 | 2024-2025 | Ventana Pdl1 Sp142 Assay |
| Eli Lilly and Company | $5,250.00 | 2025 | |
| Roche Molecular Systems, INC. | $4,529.31 | 2025 | |
| Amgen INC. | $2,744.00 | 2024 | |
| Genzyme Corporation | $2,055.00 | 2023 | |
| Astrazeneca Pharmaceuticals Lp | $1,815.00 | 2024 | |
| Leica Microsystems INC. | $229.00 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Soo Ryum Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.